Clinical Studies on Venous Thromboembolism Treatments: A Comprehensive Review
Venous Thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant global health concern, contributing substantially to cardiovascular morbidity and mortality [1]. Over the past two decades, considerable advancements have reshaped the landscape of VTE management, yet ongoing challenges persist in optimizing therapeutic strategies and balancing the delicate interplay between VTE recurrence and treatment-associated bleeding risks [1]. This comprehensive review synthesizes recent evidence from clinical studies, updated guidelines, and emerging therapeutic and diagnostic innovations, providing an academic overview suitable for both healthcare professionals and patients seeking to understand the evolving paradigms in VTE care.
Evolving Landscape of VTE Guidelines
The continuous influx of high-quality evidence from clinical trials has led to dynamic updates in international VTE guidelines, reflecting a trend towards more granular and complex management strategies [1]. These updates underscore the necessity for clinicians to access up-to-date decision-making support tools.
ASH/ISTH 2024 Update: Pediatric VTE Treatment
The 2024 joint guidelines from the American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) mark a pivotal update for pediatric VTE management, driven by a tenfold increase in pediatric VTE treatment trials [1]. While VTE incidence in the general pediatric population remains low, it is significantly higher in hospitalized children. A practice-changing recommendation is the conditional endorsement of Direct Oral Anticoagulants (DOACs), specifically dabigatran or rivaroxaban, over traditional anticoagulants like low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKAs) for appropriate pediatric patients [1]. This shift elevates DOACs to a preferred therapeutic option, though the guidelines emphasize the need for more real-world data in diverse pediatric cohorts.
NCCN 2024 Guidelines: Refining Management of Cancer-Associated Thrombosis (CAT)
For patients with cancer, VTE is a leading cause of mortality, presenting a complex clinical challenge due to the concurrent risks of thrombosis and bleeding [1]. The National Comprehensive Cancer Network (NCCN) Guidelines for Cancer-Associated Venous Thromboembolic Disease (Version 2.2024) provide updated strategies for this high-risk population. These guidelines codify the use of DOACs as a primary treatment option alongside LMWH for DVT, PE, superficial vein thrombosis, and splanchnic vein thrombosis [1]. A minimum of three months of anticoagulation is recommended, with continuation as long as the cancer is active or the patient is undergoing treatment, acknowledging the persistent prothrombotic state. Specific contraindications, such as withholding prophylactic anticoagulation for platelet counts below 50,000/µL, are also detailed [1].
ESAIC 2024 Update: Peri-operative VTE Prophylaxis
The European Society of Anaesthesiology and Intensive Care (ESAIC) updated its 2018 peri-operative VTE prophylaxis guidelines, expanding coverage to include urologic, plastics, and trauma surgery [1]. A central tenet is individualized VTE risk assessment, continuing to recommend clinical prediction tools like the Caprini score. For low-risk patients undergoing fast-track surgery, general measures such as early mobilization and optimal hydration are suggested over routine pharmacological intervention. Conversely, for very high-risk procedures, extended prophylaxis for 28–35 days post-operatively is recommended. Guidance for challenging populations, including obese patients requiring higher LMWH doses and those undergoing neurosurgery or cardiac surgery, is also provided [1].
Innovations in VTE Diagnostics: Towards Speed and Precision
The diagnostic pathway for VTE is undergoing a technological transformation, moving beyond established clinical decision rules and imaging modalities to incorporate advancements in biomarkers, imaging physics, and artificial intelligence. These innovations aim to enhance diagnostic speed, precision, and personalization, while mitigating the limitations of current tools and reducing unnecessary testing [1].
Beyond D-dimer: The Quest for Novel Biomarkers
While the D-dimer test remains crucial for ruling out VTE in low-risk patients due to its high negative predictive value, its utility is often limited by poor specificity in populations with advanced age, cancer, or inflammation, leading to false positives and unnecessary imaging [1]. This has spurred research into novel biomarkers that more accurately reflect VTE pathophysiology.
Promising candidates include E-selectin and P-selectin, adhesion molecules involved in thrombus formation and inflammation, which have shown potential for diagnostic accuracy comparable to D-dimer but with higher specificity [1]. However, recent studies have yielded mixed results regarding their prognostic utility, particularly in predicting short-term mortality in acute symptomatic PE [1]. Further research is needed, especially in the context of Cancer-Associated Thrombosis (CAT), where selectin molecules show promise [1].
In CAT, the Khorana score is a widely used risk assessment model for VTE prophylaxis in cancer patients initiating chemotherapy, but it is limited by low sensitivity and specificity, and D-dimer levels are often elevated at baseline [1]. Ongoing research is exploring biomarkers that reflect the unique prothrombotic state of malignancy, including the implication of genotypes like EGFR mutation in non-small-cell lung cancer [1]. High-throughput proteomic screens are identifying new molecular candidates, enhancing our understanding of thrombus pathophysiology. A recent meta-analysis identified multiple routinely available biomarkers, such as factor VIII and fibrinogen, that can be integrated into VTE risk models for this population [1]. Multi-omics approaches, such as a 2024 metabolomic profiling study identifying a distinct metabolic signature in red blood cells of acute VTE patients, show exceptionally high diagnostic performance [1]. However, many of these novel biomarkers require rigorous testing in large, prospective clinical validation trials [1].
Advanced Imaging: Photon-Counting CT (PCCT)
Photon-counting CT (PCCT) represents a fundamental shift in CT imaging technology, directly converting individual X-ray photon energies into electrical signals [1]. This technology outperforms conventional energy-integrating detectors, offering improved spatial resolution, reduced beam artifacts, and clearer visualization of fine anatomical details, such as lung parenchyma architecture [1]. PCCT also provides superior iodine signal in vessels, allowing for better discrimination of small pulmonary vessel opacification, and reduces motion artifacts. Crucially, PCCT has demonstrated the ability to achieve significant radiation dose reductions (up to 50%) while improving image quality, and can reduce contrast media, benefiting patients with impaired renal function [1].
Artificial Intelligence in VTE Diagnosis and Management
Artificial intelligence (AI), particularly machine learning (ML) and deep learning algorithms, holds transformative potential for improving VTE prevention, diagnosis, and management [1]. AI is being explored to identify at-risk patients and guide prophylactic strategies [1]. A promising application lies in image analysis for diagnosis, addressing limitations of operator dependency, false positives/negatives, and procedural risks associated with CUS and CTPA. AI-assisted CUS and CTA analysis, including U.S.-authorized algorithms like CINA-iPE for detecting incidental PE on CTPA, have demonstrated high specificity and sensitivity [1]. AI could serve as a second reader for radiologists, automatically detecting PE and incidental PE, thereby reducing missed or delayed diagnoses and improving diagnostic accuracy [1].
Beyond image analysis, AI is being leveraged to optimize clinical workflows and care coordination. AI tools can flag suspected PE and incidental PE, triggering alerts to multidisciplinary response teams and prioritizing urgent cases, leading to more timely management. AI-assisted reprioritization can significantly reduce report turnaround times and median detection times for incidental PE [1]. Despite its broad potential, significant hurdles remain, including the need for large, diverse, and well-annotated datasets, addressing inter-reader variability, data privacy concerns, lack of reimbursement models, and ethical considerations [1]. False positives can also lead to radiologist alert fatigue, emphasizing the need for careful optimization and robust IT infrastructure [1]. Clinical management studies incorporating these technologies are needed before widespread adoption [1].
Therapeutic Advancements
The treatment landscape for VTE has undergone significant evolution, with a notable shift towards more convenient and effective anticoagulant therapies, alongside advancements in interventional approaches.
Direct Oral Anticoagulants (DOACs)
The advent of direct oral anticoagulants (DOACs), such as rivaroxaban, apixaban, edoxaban, and dabigatran, has greatly simplified VTE treatment for most patients [2]. These agents are generally recommended over vitamin K antagonists (VKAs) due to their predictable pharmacokinetics, fewer drug-drug interactions, and no requirement for routine coagulation monitoring [2]. However, LMWH and VKAs still retain a persisting role in select patient groups [2]. Following an initial 3 to 6 months of anticoagulation, patients with major transient provoking factors can safely discontinue therapy [2]. The decision regarding long-term anticoagulation hinges on balancing the risk of recurrent VTE against bleeding risk, necessitating shared decision-making with patients [2].
Interventional Therapies
For patients presenting with high-risk features, advanced reperfusion therapies, including thrombolysis and/or interventional approaches, may be beneficial in reducing early mortality and long-term morbidity [2]. These therapies are typically reserved for severe cases, such as massive pulmonary embolism, where rapid clot removal is critical.
Emerging Promise of Factor XI Inhibition
Factor XI inhibition has shown considerable promise in clinical trials for both the prevention and treatment of VTE [1]. This novel class of anticoagulants aims to reduce thrombotic risk with a potentially lower bleeding risk compared to conventional anticoagulants, representing a significant area of ongoing research and development [1].
Special Populations
Managing VTE in specific patient populations requires tailored approaches due to unique risk factors and treatment considerations.
Cancer-Associated Thrombosis (CAT)
As previously discussed, CAT presents a complex challenge due to the heightened prothrombotic state and increased bleeding risk in cancer patients. The NCCN guidelines provide specific recommendations, emphasizing DOACs and LMWH, and extended duration of anticoagulation [1].
Pediatric VTE
The ASH/ISTH guidelines have significantly advanced the management of pediatric VTE, with DOACs now conditionally recommended as a preferred option, highlighting the importance of age-specific evidence and ongoing research in this vulnerable population [1].
Challenges and Future Directions
Despite significant progress, several challenges and areas for future research remain in VTE management. Balancing the risk of recurrent VTE with the risk of bleeding remains a central clinical dilemma, requiring individualized patient assessment and shared decision-making [2]. The need for more real-world data on novel therapies and diagnostic tools, particularly in diverse patient cohorts, is crucial for validating their clinical utility and ensuring equitable application [1]. Ethical considerations surrounding the integration of AI into clinical practice, including data privacy and potential biases, also warrant careful attention [1]. Continued research into novel biomarkers, advanced imaging techniques, and targeted therapies holds the key to further refining VTE prevention, diagnosis, and treatment, ultimately improving patient outcomes.
Disclaimer
This blog post is intended for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
References
[1] Bedrouni, W., Bedrouni, M., & Douketis, J. (2025). New Horizons in Venous Thromboembolism Management: A Narrative Review. *Journal of Clinical Medicine*, *14*(21), 7668. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12609676/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12609676/) [2] Cox, C., & Roberts, L. N. (2025). Basics of diagnosis and treatment of venous thromboembolism. *Journal of Thrombosis and Haemostasis*, *23*(4), 1185-1202. [https://www.sciencedirect.com/science/article/pii/S1538783625000522](https://www.sciencedirect.com/science/article/pii/S1538783625000522)